Nicholas Piramal Says Contract Research Progressing, Avecia Unit Profitable
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Nicholas Piramal said its growing contract research business, forecast to be a separately listed unit by June, has four potential compounds in Phase I to Phase II trials while its Avecia Pharmaceuticals unit has turned profitable
You may also be interested in...
PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms
NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country
PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms
NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country
Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight
MUMBAI - A new patent law to protect intellectual property and in-depth experience in clinical trials and manufacturing has helped Indian drug firms such as Piramal Healthcare become equal partners with multinational counterparts in sharing risks, costs and profits, according to a senior company executive